Skip to main content

Table 1 Characteristics of eligible trials [7,8,9, 21,22,23,24,25,26,27,28,29,30,31,32,33,34]

From: Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis

  1. HR high risk, NA not available, HSCT haematopoeitic stem cell transplantation, risk of bias: A, bias due to randomization; B, bias due to deviations from intended intervention; C, bias due to missing data; D, bias due to outcome measurement; E, bias due to selection of reported result; F, overall bias. Judgement: green cross, low; yellow minus, some concerns; red cross, high
Back to article page

Systematic Reviews

ISSN: 2046-4053